Acrongenomics Inc., a Swiss life science venture company and Molecular Vision Ltd., a spin-out from the Imperial College London, said they have signed a memorandum of understanding to jointly develop diagnostic devices for diabetes, drug abuse, STDs and cardiovascular diseases.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.